Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital

被引：25

作者：

Bruder-Nascimento A. ^{[1
]}

Camargo C.H. ^{[1
]}

Sugizaki M.F. ^{[1
]}

Sadatsune T. ^{[1
]}

Montelli A.C. ^{[1
]}

Mondelli A.L. ^{[2
]}

Bagagli E. ^{[1
]}

机构：

[1] Botucatu Biosciences Institute, Sao Paulo State University, Botucatu

[2] Medical School, Sao Paulo State University, Botucatu

来源：

BMC Research Notes | / 3卷 / 1期

基金：

巴西圣保罗研究基金会;

关键词：

Itraconazole; Candida Species; Bloodstream Infection; Latin American Country; Peritoneal Fluid;

D O I：

10.1186/1756-0500-3-1

中图分类号：

学科分类号：

摘要：

Background. Species identification and antifungal susceptibility tests were carried out on 212 Candida isolates obtained from bloodstream infections, urinary tract infections and dialysis-associated peritonitis, from cases attended at a Brazilian public tertiary hospital from January 1998 to January 2005. Findings. Candida albicans represented 33% of the isolates, Candida parapsilosis 31.1%, Candida tropicalis 17.9%,Candida glabrata 11.8%, and others species 6.2%. In blood culture, C. parapsilosis was the most frequently encountered species (48%). The resistance levels to the antifungal azoles were relatively low for the several species, except for C. tropicalis and C. glabrata. Amphotericin B resistance was observed in 1 isolate of C. parapsilosis. Conclusions. The species distribution and antifungal susceptibility herein observed presented several epidemiological features common to other tertiary hospitals in Latin American countries. It also exhibited some peculiarity, such as a very high frequency of C. parapsilosis both in bloodstream infections and dialysis-associated peritonitis. C. albicans also occurred in an important number of case infections, in all evaluated clinical sources. C. glabrata presented a high proportion of resistant isolates. The data emphasize the necessity to carry out the correct species identification accompanied by the susceptibility tests in all tertiary hospitals. © 2010 Bagagli et al; licensee BioMed Central Ltd.

引用

共 31 条

[1]

White T.C., Marr K.A., Bowden R.A., Clinical, cellular, and molecular factors that contribute to antifungal drug resistance, Clin Microbiol Rev, 11, pp. 382-402, (1998)

[2]

Colombo A.L., Nucci M., Park B.J., Nouer S.A., Arthington-Skaggs B., Da Matta D.A., Warnock D., Morgan J., Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers, J Clin Microbiol, 44, pp. 2816-2823, (2006)

[3]

Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B., Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, pp. 309-317, (2004)

[4]

Passos X.S., Costa C.R., Arajo C.R., Nascimento E.S., Souza L.K.E., Fernandes Ode F., Sales W.S., Silva Mdo R., Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital, Mycopathologia, 163, pp. 145-151, (2007)

[5]

Medrano D.J., Brilhante R.S., Cordeiro A.R., Rocha M.F., Rabenhorst S.H., Sidrim J.J., Candidemia in a Brazilian hospital: The importance of Candida parapsilosis, Rev Inst Med Trop Sao Paulo, 48, pp. 17-20, (2006)

[6]

Snydman D.R., Shifting in patterns in the epidemiology of nosocomial Candida infections, Chest, 123, pp. 500-503, (2003)

[7]

Sobel J.D., The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia, Curr Infct Dis Rep, 8, pp. 427-433, (2006)

[8]

Aquino V.R., Lunardi L.W., Goldani L.Z., Barth A.L., Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in Southern Brazil, Braz J Infect Dis, 9, pp. 411-418, (2005)

[9]

Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Suscetibility Program, 2001, J Clin Microbiol, 41, pp. 1440-1446, (2003)

[10]

Yang Y.L., Ho Y.A., Cheng H.H., Ho M., Lo H.J., Susceptibilities of Candida species to amphotericin B and fluconazole: The emergence of fluconazole resistance in Candida tropicalis, Infect Control Hosp Epidemiol, 25, pp. 60-64, (2004)

← 1 2 3 4 →